NCT00219986已完成1 期
A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- To determine the antiviral activity of the combination of 3 monoclonal antibody infusions as an adjunct to HAART
研究概览
简要总结
Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. Acute or early HIV-1 infection at the time of HAART initiation defined by HIV-1 RNA detectable with a negative serology or a negative detuned ELISA. HAART for at least 15 months and no more than 1 detectable HIV-1 RNA value (above the 50 copy/mL) for at least 6 months prior to screening.
- •Laboratory values
- •Absolute neutrophil count (ANC) equal to or greter than 750/mm
- •Hemoglobin equal to or greater than 9.5 g/dL.
- •Platelet count equal to or greater than 50,000/mm
- •Calculated creatinine clearance (CrCl) equal to or greater than 80 mL/min according to the Cockcroft-Gault formula:
- •Men: (140-age in years) x (wt in kg) = CrCl (mL/min) 72 x (serum creatinine in mg/dL)
- •Female: (140-age in years) x (wt in kg) x 0.85 = CrCl (mL/min) 72 x (serum creatinine in mg/dL)
- •AST (SGOT), ALT (SGPT), and alkaline phosphatase equal to or less than 5 x ULN.
- •Total bilirubin equal to or less than 2.5 x ULN.
- •Serum Lipase equal to or less than 1.5 x ULN
- •Negative serum pregnancy test within 14 days. All females of childbearing potential must agree to practice active birth control measures (barrier methods such as condoms, diaphragms, cervical cap, etc. or an intrauterine device such as a coil) to avoid pregnancy while receiving the study drugs and for 30 days after the last dose of the study drugs. Additionally, men enrolled in the study should practice active birth control for the same period of time with their female partners of childbearing potential.
- •Men and women age >18 years. Ability and willingness of subject to give written informed consent -
排除标准
- •More than 1 detectable HIV-1 RNA value (>50 copies/mL) within 6 months of screening visit
- •Pregnancy and breast-feeding.
- •Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
- •Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry.
结局指标
主要结局
To determine the antiviral activity of the combination of 3 monoclonal antibody infusions as an adjunct to HAART
次要结局
- To determine the safety of the combination of 3 monoclonal antibody infusions as an adjunct to HAART
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate PneumoniaSARS VirusNCT04453384Nantes University Hospital416
已完成
2 期
A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy RegimenHIV-1 InfectionNCT01714414Michael Hoelscher120
已完成
3 期
Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in UgandaHIVNCT00339456National Institute of Allergy and Infectious Diseases (NIAID)155
已完成
1 期
Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19COVID-19NCT04514302Hospital San Jose Tec de Monterrey32
已完成
2 期
Convalescent Plasma for Treatment of COVID-19 Patients With PneumoniaCorona Virus InfectionSARS-CoV 2SARS PneumoniaPneumoniaNCT04374565University of Virginia29